Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 2/20 | 0.58 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.34 |
| ▸ | CFD | P00746 | 2/20 | 0.34 |
| ▸ | CMA1 | P23946 | 2/20 | 0.34 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1042843 | 1.00 | METTL3 (0.58) | METTL3P2RX7NTRK1CFDCMA1 | |
| SCHEMBL1042974 | 0.93 | METTL3 (0.64) | METTL3NTRK1CFDCMA1PLA2G4A | |
| SCHEMBL1042976 | 0.93 | METTL3 (0.64) | METTL3NTRK1CFDCMA1PLA2G4A | |
| SCHEMBL1045793 | 0.92 | METTL3 (0.65) | METTL3P2RX7CFDP2RX3MRGPRX4 | |
| SCHEMBL29875102 | 0.92 | METTL3 (0.65) | METTL3P2RX7CFDP2RX3MRGPRX4 | |
| SCHEMBL14611521 | 0.92 | METTL3 (0.54) | METTL3P2RX7CFDPLA2G4AP2RX3 | |
| SCHEMBL1045792 | 0.92 | METTL3 (0.65) | METTL3P2RX7CFDP2RX3MRGPRX4 | |
| SCHEMBL1044583 | 0.91 | METTL3 (0.54) | METTL3P2RX7CFDP2RX3MRGPRX4 | |
| SCHEMBL1044585 | 0.91 | METTL3 (0.54) | METTL3P2RX7CFDP2RX3MRGPRX4 | |
| SCHEMBL1043000 | 0.91 | METTL3 (0.57) | METTL3NTRK1CFDPLA2G4AMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1564210-B9 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC (JP) | 2010-03-31 | — | — | EP | claimed |
| EP-1564210-B1 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC (JP) | 2009-09-16 | — | — | EP | claimed |
| CN-100375742-C | 4-oxoquinoline compounds and utilization thereof as HIV integrase inhibitors | JAPAN TOBACCO INC (JP) | 2008-03-19 | — | — | CN | claimed |
| CN-1692101-A | 4-oxoquinoline compounds and utilization thereof as HIV integrase inhibitors | JAPAN TOBACCO INC (JP) | 2005-11-02 | — | — | CN | claimed |
| EP-1564210-A1 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-08-17 | — | — | EP | claimed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-4059923-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | Japan Tobacco Inc. (JP) | 2022-09-21 | — | — | EP | disclosed |
| US-20200101061-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2020-04-02 | — | — | US | disclosed |
| EP-3406596-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | Japan Tobacco Inc. (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. | 2015-06-25 | — | — | US | disclosed |
| US-20130172344-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. | 2013-07-04 | — | — | US | disclosed |
| US-20130172344-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. | 2013-07-04 | — | — | US | disclosed |
| EP-2161258-A2 | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor | Japan Tabacco Inc. (JP) | 2010-03-10 | — | — | EP | disclosed |
| EP-1564210-B1 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC (JP) | 2009-09-16 | — | — | EP | disclosed |
| CN-100375742-C | 4-oxoquinoline compounds and utilization thereof as HIV integrase inhibitors | JAPAN TOBACCO INC (JP) | 2008-03-19 | — | — | CN | disclosed |
| US-7176220-B2 | 4-oxoquinoline compound and use thereof as pharmaceutical agent | JAPAN TOBACCO INC. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20060217413-A1 | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2006-09-28 | — | — | US | disclosed |
| CN-1692101-A | 4-oxoquinoline compounds and utilization thereof as HIV integrase inhibitors | JAPAN TOBACCO INC (JP) | 2005-11-02 | — | — | CN | disclosed |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1564210-A1 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, CDKL4, IMPDH2 | METTL3 1398/4885P2RX7 3526/4885NTRK1 4702/4885 |
| US-20200101061-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, CDKL4, IMPDH2 | METTL3 1398/4885P2RX7 3526/4885NTRK1 4702/4885 |
| US-20130172344-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | IMPDH1, CDKL4, IMPDH2 | METTL3 1861/4885P2RX7 4015/4885NTRK1 4624/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | METTL3 1258/4885P2RX7 3047/4885NTRK1 4725/4885 |
| US-20060217413-A1 | 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor | IMPDH1, CDKL4, IMPDH2 | METTL3 1861/4885P2RX7 4015/4885NTRK1 4624/4885 |
| US-20050239819-A1 | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors | IMPDH1, IMPDH2, TYMP | METTL3 1746/4885P2RX7 3947/4885NTRK1 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.